Literature DB >> 10934984

Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers.

J M Wright1.   

Abstract

Elevated blood pressure is associated with an increased risk of cardiovascular illness and death. Efforts to reduce that risk have led to recommendations for a wide array of nondrug and drug therapies. Choosing the optimal first-line drug for hypertensive patients should address a hierarchy of treatment goals: decrease in morbidity and mortality associated with hypertension, decrease in blood pressure, good tolerance, dosing convenience and low cost. This article examines the evidence for beta-blockers as a class of first-line antihypertensive drugs in light of these treatment goals. The evidence indicates that beta-blockers are probably not as effective in reducing morbidity and mortality as low-dose thiazide diuretics and that there may be significant differences in effectiveness among various beta-blockers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934984      PMCID: PMC80212     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  18 in total

1.  MAPHY and the two arms of HAPPHY.

Authors:  I Holme
Journal:  JAMA       Date:  1989-12-15       Impact factor: 56.272

2.  Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol.

Authors:  J P Boissel; A Leizorovicz; H Picolet; J C Peyrieux
Journal:  Am J Cardiol       Date:  1990-08-01       Impact factor: 2.778

3.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Authors:  B Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; P O Wester
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

4.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

5.  Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study.

Authors:  J Wikstrand; I Warnold; J Tuomilehto; G Olsson; H J Barber; K Eliasson; D Elmfeldt; B Jastrup; N B Karatzas; J Leer
Journal:  Hypertension       Date:  1991-04       Impact factor: 10.190

6.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

7.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

8.  The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group.

Authors: 
Journal:  Eur Heart J       Date:  1987-10       Impact factor: 29.983

9.  Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.

Authors:  L Wilhelmsen; G Berglund; D Elmfeldt; T Fitzsimons; H Holzgreve; J Hosie; P E Hörnkvist; K Pennert; J Tuomilehto; H Wedel
Journal:  J Hypertens       Date:  1987-10       Impact factor: 4.844

10.  Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.

Authors: 
Journal:  BMJ       Date:  1992-02-15
View more
  10 in total

Review 1.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

2.  The value of industry-sponsored studies of initial antihypertensive therapies.

Authors:  J J Caro; K Payne
Journal:  CMAJ       Date:  2001-06-26       Impact factor: 8.262

3.  First-line drugs for hypertension.

Authors:  J D Spence
Journal:  CMAJ       Date:  2001-01-23       Impact factor: 8.262

Review 4.  What are the elements of good treatment for hypertension?

Authors:  C D Mulrow; M Pignone
Journal:  BMJ       Date:  2001-05-05

Review 5.  Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme inhibitors.

Authors:  J M Wright
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

Review 6.  Beta-blockers for hypertension.

Authors:  Charles S Wiysonge; Hazel A Bradley; Jimmy Volmink; Bongani M Mayosi; Lionel H Opie
Journal:  Cochrane Database Syst Rev       Date:  2017-01-20

Review 7.  The double-edged sword of COX-2 selective NSAIDs.

Authors:  James M Wright
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

Review 8.  Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.

Authors:  Ezequiel Balmori Melian; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.

Authors:  Gavin W K Wong; Heidi N Boyda; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2016-03-10

10.  First-line first? Trends in thiazide prescribing for hypertensive seniors.

Authors:  Steve Morgan; Kenneth L Bassett; James M Wright; Lixiang Yan
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.